MORRIS PLAINS, N.J., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported revenues of $4.9 million and a net loss of $2.2 million, or $0.03 per share, for the first quarter of fiscal year 2009, which ended September 30, 2008. This compares to revenues of $0.8 million and a net loss of $4.6 million, or $0.06 per share, for the same period last year.
